Baptist Cancer Services offers patients participation in clinical trials. Following are the clinical trials currently available as of February 2014. For more information, contact our Baptist Cancer Services Navigator, Tonya Ball, at 601-974-6238.
Amgen – randomized study to assess the effect of prophylactic intervention with Naproxen vs. Claritin vs. no treatment on bone pain in breast cancer patients receiving adjuvant chemotherapy and Neulasta; Amgen - prospective study of the relationship between chemotherapy dose and mortality in early stage breast cancer
Novartis - double-blind study of LEE011 with Femara for hormone positive advanced breast cancer with no prior therapy for advanced or metastatic disease
Puma Biotechnology - Neratinib plus Xeloda versus Tykerb plus Xeloda in patients with HER 2 positive metastatic breast cancer who have received two or more regimens for metastatic disease
Sanofi - Observational trial for metastatic colon cancer patients receiving Zaltrap in combination with FOLFIRI
Novartis - study of switching patients who have received Gleevec for one year and achieved a partial response to Tasigna
Novartis - study of oral LDK378 in ALK positive non-small cell lung cancer patients who were previously treated with Xalkori
Randomized Study of Idelalisib with Rituxan and Treanda for previously treated indolent non-hodgkins lymphoma
Novartis - a phase 3 study trial of LGYX818 and MEK 162 and LX818 monotherapy compared with Vemurafenib in metastatic melanoma
Onyx - Phase 2 study of weekly Kyprolis with decadron for progressive myeloma
Celgene– phase 3 randomized, double-blind study to compare efficacy and safety of Oral Azacitidine versus placebo plus best supportive care in subjects with RBC transfusion dependent anemia and thrombocytopenia due to IPSS lower risk MDS
What can we help you find?